Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Acquired by Nuveen Asset Management LLC

Nuveen Asset Management LLC boosted its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 6.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 519,253 shares of the biopharmaceutical company’s stock after purchasing an additional 31,331 shares during the period. Nuveen Asset Management LLC owned approximately 0.49% of Intra-Cellular Therapies worth $43,368,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of ITCI. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Intra-Cellular Therapies by 10.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company’s stock valued at $1,878,000 after purchasing an additional 2,157 shares during the last quarter. Barclays PLC grew its position in Intra-Cellular Therapies by 282.0% in the third quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company’s stock worth $2,521,000 after acquiring an additional 25,435 shares in the last quarter. Merit Financial Group LLC bought a new stake in Intra-Cellular Therapies in the fourth quarter worth $206,000. SG Americas Securities LLC boosted its stake in shares of Intra-Cellular Therapies by 204.4% during the 4th quarter. SG Americas Securities LLC now owns 12,917 shares of the biopharmaceutical company’s stock worth $1,079,000 after acquiring an additional 8,673 shares in the last quarter. Finally, TimesSquare Capital Management LLC boosted its position in Intra-Cellular Therapies by 91.8% during the fourth quarter. TimesSquare Capital Management LLC now owns 840,269 shares of the biopharmaceutical company’s stock worth $70,179,000 after purchasing an additional 402,186 shares during the period. Institutional investors and hedge funds own 92.33% of the company’s stock.

Intra-Cellular Therapies Price Performance

ITCI opened at $131.87 on Tuesday. The company has a market cap of $14.05 billion, a price-to-earnings ratio of -151.57 and a beta of 0.69. The firm has a 50 day simple moving average of $131.80 and a 200 day simple moving average of $114.53. Intra-Cellular Therapies, Inc. has a fifty-two week low of $64.09 and a fifty-two week high of $131.98.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The company had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. As a group, analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Analysts Set New Price Targets

ITCI has been the subject of a number of recent analyst reports. StockNews.com initiated coverage on shares of Intra-Cellular Therapies in a report on Thursday, May 15th. They set a “hold” rating for the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. Royal Bank of Canada restated a “sector perform” rating and set a $132.00 price target (up previously from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Cantor Fitzgerald reissued a “neutral” rating and set a $132.00 price target on shares of Intra-Cellular Therapies in a report on Wednesday, April 2nd. Finally, Mizuho downgraded Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $140.00 to $132.00 in a research report on Monday, February 24th. Eleven analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $109.70.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.